Velpanat

Velpanat (sofosbuvir + velpatasvir) - epclusa is a new medication used to treat hepatitis c. It is a combination pill containing sofosbuvir (sold separately as sovaldi) plus velpatasvir. It was approved in europe in july 2016 for treatment of adults with all genotypes (1, 2, 3, 4, 5 and 6) of chronic hepatitis c. Epclusa is the first pangenotypic interferon-free hepatitis c treatment regimen, meaning it works against all hepatitis c genotypes. It is more effective than the older harvoni combination (sofosbuvir + ledipasvir) for people with genotype 3. Some people with harder-to-treat disease may do better if they take epclusa with ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis c such as liver cancer or needing a liver transplant.